Zargis Cardioscan(TM) Unveiled Through Global Marketing and Distribution Alliance With 3M Company
25 August 2009 - 10:00PM
PR Newswire (US)
STAMFORD, Conn., Aug. 25 /PRNewswire-FirstCall/ -- Zargis Medical
Corp., a spin-off from Siemens Corporate Research (NYSE:SI) and a
majority-owned subsidiary of Speedus Corp. (NASDAQ:SPDE), today
announced that it has begun selling its Zargis Cardioscan(TM) heart
sound analysis software, along with 3M's (NYSE:MMM) just-released
Bluetooth -enabled 3M(TM) Littmann Electronic Stethoscope Model
3200, as part of its previously announced exclusive multi-year
global marketing alliance with 3M. This marketing alliance provides
Zargis with a wide-range of global marketing and promotional
opportunities along with exclusive rights to sell its products
through the world-wide distribution network of the 3M(TM) Littmann
brand. Zargis Cardioscan software, the 3M(TM) Littmann Electronic
Stethoscope Model 3200 and access to ZargisTelemed(TM) -- Zargis'
Internet-based telemedicine portal -- can now be purchased online
at http://www.zargis.com/. "The ability to record and automatically
analyze heart sounds can help improve a clinician's confidence,
document complex auscultations, and may keep some patients from
going through additional, unnecessary testing," stated Joseph
Tartaglia, MD, a practicing cardiologist in White Plains, NY, and
clinical assistant professor of medicine at New York Medical
College in Valhalla, NY. Cardioscan heart sound analysis software
is designed to support physicians in analyzing and interpreting
cardiac sounds which can be signs of heart disease. Cardioscan
connects wirelessly to the Bluetooth -enabled 3M(TM) Littmann
Electronic Stethoscope Model 3200, and integrates with the
ZargisTelemed portal -- a HIPAA-compliant feature of Cardioscan
allowing users to easily share heart sounds recordings, analyzed
results and comments with colleagues via the Internet. "At a time
when our nation is focused on leveraging technology to improve
healthcare efficiency, these devices represents breakthroughs in
auscultation that have the potential to reduce unnecessary
referrals, and help clinicians detect pathologic heart murmurs
earlier in the treatment cycle," stated John Kallassy, CEO of
Zargis Medical. "We believe that the use of our software could
enhance the physician experience during every patient exam where a
stethoscope is used." Zargis and select distributors of 3M(TM)
Littmann Brand Products will be selling Cardioscan for $395 (retail
price) per licensed user -- a price point intended to make the
device affordable to a variety of healthcare professionals around
the world. In addition, access to the ZargisTelemed portal will be
priced at $10 per month per licensed user. About 3M Health Care 3M
Health Care, one of 3M's six major business segments, provides
world-class innovative products and services to help health care
professionals improve the practice, delivery and outcome of patient
care in medical, oral care, drug delivery and health information
markets. For more information, visit http://www.3m.com/. About
Zargis Medical Corp. Zargis Medical Corp. develops advanced
diagnostic decision support products and services for primary care
physicians, pediatricians, cardiologists and other healthcare
professionals. Zargis was formed in 2001 when Siemens Corporate
Research, a division of Siemens AG (NYSE:SI), and Speedus Corp.
(NASDAQ:SPDE) co-invested to develop and market an advanced
acoustic technology designed to detect heart abnormalities
identified through analysis of heart sounds. For additional
information about Zargis or Speedus Corp., contact Peter Hodge at
888.773.3669 (ext. 23) or , or visit the following Web sites:
http://www.zargis.com/ and http://www.speedus.com/. Statements
contained herein that are not historical facts, including but not
limited to statements about the Company's product, corporate
identity and focus, may be forward-looking statements that are
subject to a variety of risks and uncertainties. There are a number
of important factors that could cause actual results to differ
materially from those expressed in any forward-looking statements
made by the Company, including, but not limited to, the continuing
development of the Company's sales, marketing and support efforts.
DATASOURCE: Speedus Corp. CONTACT: Peter Hodge for Zargis and
Speedus Corp, 1-888-773-3669 (ext. 23), Web Site:
http://www.speedus.com/
Copyright
Speedus (CE) (USOTC:SPDE)
Historical Stock Chart
From Jun 2024 to Jul 2024
Speedus (CE) (USOTC:SPDE)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Speedus Corp (CE) (OTCMarkets): 0 recent articles
More Speedus (MM) News Articles